Efforts to decrease the spread of HIV worldwide continue at a rapid pace. With the development of new biomedical interventions and findings from pivotal clinical trials, a new framework for short-term and long-term prevention strategies is emerging. It is clear that biomedical-based approaches targeted at the highest risk populations have the greatest potential to have a short-term impact. Unfortunately, challenges with adherence in healthy populations at risk are now well-recognized, and competing health care priorities in the context of fragile delivery infrastructures pose formidable obstacles to implementation. We need better ways to identify high-risk populations, sophisticated understanding of the behavioral parameters that can ensure adherence, and the development of better strategies to provide sustained delivery of preexposure prophylaxis (PrEP). In the long term, we need an effective vaccine—a path that has proven to be rocky. Research facilitating an increased understanding of immune responses and what represents effective responses to prevent HIV acquisition should facilitate progress. While we wait for that time, PrEP offers the best strategy for short-term impact.
Get full access to this article
View all access options for this article.
References
1.
ReesH, Delany-MoretlweS, LombardC, et al.: FACTS 001 Phase III Trial of Pericoital Tenofovir 1% Gel for HIV Prevention in Women. CROI 2015. Boston, MA, 2015.
2.
MarrazzoJM, RamjeeG, RichardsonBA, et al.: Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med, 2015; 372(6):509–518.
3.
The LancetH. Antiretroviral gels: Facing the FACTS. Lancet HIV, 2015; 2(4):e115.
4.
Palanee-PhillipsT, SchwartzK, BrownER, et al.: Characteristics of women enrolled into a randomized clinical trial of dapivirine vaginal ring for HIV-1 prevention. PLoS One, 2015; 10(6):e0128857.
5.
BurtonDR and MascolaJR: Antibody responses to envelope glycoproteins in HIV-1 infection. Nat Immunol, 2015; 16(6):571–576.
6.
CaskeyM, KleinF, LorenziJC, et al.: Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015; 522(7557):487–491.
7.
SeidmanD, WeberS, AaronE, et al.: The FACTS about women and pre-exposure prophylaxis. Lancet HIV, 2015; 2(6):e228.
8.
CohenMS, ChenYQ, McCauleyM, et al.: Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med, 2011; 365(6):493–505.
9.
Abdool KarimQ, Abdool KarimSS, FrohlichJA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science, 2010; 329(5996):1168–1174.
10.
ParikhUM, DobardC, SharmaS, et al.: Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol, 2009; 83(20):10358–10365.
11.
ClarkJT, ClarkMR, ShelkeNB, et al.: Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy. PLoS One, 2014; 9(3):e88509.
12.
van der StratenA, MusaraP, EtimaJ, et al.: Disclosure of pharmacokinetic (PK) drug results promotes open discourse on non-adherence among women in VOICE. AIDS Res Hum Retroviruses, 2014; 30(S1):A42–A43.
13.
FriendDR, ClarkJT, KiserPF, and ClarkMR: Multipurpose prevention technologies: Products in development. Antiviral Res, 2013; 100(Suppl):S39–47.
14.
GeissY and DietrichU: Catch me if you can—The race between HIV and neutralizing antibodies. AIDS Rev, 2015; 17(2):107–113.
15.
DerdeynCA, MoorePL, and MorrisL: Development of broadly neutralizing antibodies from autologous neutralizing antibody responses in HIV infection. Curr Opin HIV AIDS, 2014; 9(3):210–216.
16.
JardineJ, JulienJP, MenisS, et al.: Rational HIV immunogen design to target specific germline B cell receptors. Science, 2013; 340(6133):711–716.
17.
Doria-RoseNA and JoyceMG: Strategies to guide the antibody affinity maturation process. Curr Opin Virol, 2015; 11:137–147.
18.
MoodyMA, YatesNL, AmosJD, et al.: HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages. J Virol, 2012; 86(14):7496–7507.
19.
CorreiaBE, BatesJT, LoomisRJ, et al.: Proof of principle for epitope-focused vaccine design. Nature, 2014; 507(7491):201–206.
20.
ImpagliazzoA, MilderF, KuipersH, et al.: A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science, 2015; 349(6254):1301–1306.
21.
HaydenEC: Almighty antibodies? A new wave of antibody-based approaches aims to combat HIV. Nat Med, 2015; 21(7):657–659.
22.
DealCE and BalazsAB: Engineering humoral immunity as prophylaxis or therapy. Curr Opin Immunol, 2015; 35:113–122.
23.
HansenSG, FordJC, LewisMS, et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature, 2011; 473(7348):523–527.
24.
HansenSG, SachaJB, HughesCM, et al.: Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science, 2013; 340(6135):1237874.
25.
Rerks-NgarmS, PitisuttithumP, NitayaphanS, et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med, 2009; 361(23):2209–2220.
26.
HaynesBF, GilbertPB, McElrathMJ, et al.: Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med, 2012; 366(14):1275–1286.
27.
ClinicalTrials.gov Identifier: NCT02404311. 2015.
28.
WHO guidelines: Prevention of Mother-to-Child Transmission (PMCTC). www.avert.org/world-health-organisation-who-pmtct-guidelines.htm.
29.
GrantRM, LamaJR, AndersonPL, et al.: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med, 2010; 363(27):2587–2599.
30.
AndersonPL, GliddenDV, LiuA, et al.: Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med, 2012; 4(151):151ra125.
31.
VolkJE, MarcusJL, PhengrasamyT, et al.: No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis, 2015; 61(10):1601–1603.
32.
AndrewsCD, SpreenWR, MohriH, et al.: Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. Science, 2014; 343(6175):1151–1154.
33.
KovarovaM, CouncilOD, DateAA, et al.: Nanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmission. PLoS Pathog, 2015; 11(8):e1005075.
34.
SpreenWR, MargolisDA, and PottageJCJr: Long-acting injectable antiretrovirals for HIV treatment and prevention. Curr Opin HIV AIDS, 2013; 8(6):565–571.
35.
BoffitoM, JacksonA, OwenA, and BeckerS: New approaches to antiretroviral drug delivery: Challenges and opportunities associated with the use of long-acting injectable agents. Drugs, 2014; 74(1):7–13.
36.
McChesneyMB, CollinsJR, LuD, et al.: Occult systemic infection and persistent simian immunodeficiency virus (SIV)-specific CD4(+)-T-cell proliferative responses in rhesus macaques that were transiently viremic after intravaginal inoculation of SIV. J Virol, 1998; 72(12):10029–10035.
37.
MaZM, AbelK, RourkeT, WangY, and MillerCJ: A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations. J Virol, 2004; 78(24):14048–14052.
38.
TascaS, TsaiL, TrunovaN, et al.: Induction of potent local cellular immunity with low dose X4 SHIV(SF33A) vaginal exposure. Virology, 2007; 367(1):196–211.
39.
AndrewsCD, YuehYL, SpreenWR, et al.: A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge. Sci Transl Med, 2015; 7(270):270ra274.
40.
CelumCL, Delany-MoretlweS, McConnellM, et al.: Rethinking HIV prevention to prepare for oral PrEP implementation for young African women. J Int AIDS Soc, 2015; 18(4Suppl 3):20227.
41.
AuerbachJD, KinskyS, BrownG, and CharlesV: Knowledge, attitudes, and likelihood of pre-exposure prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care STDS, 2015; 29(2):102–110.
42.
WHO Guidelines: Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. 2015.
